The JCO publication describes a prospective analysis (prior to unblinding) performed in the intended target tumor population, patients with IDH mutant grade 3 (without CDKN2A/B homozygous deletion) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback